Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» CAR-T
CAR-T
Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval
Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval
BioSpace
Anixa Biosciences
FDA
CAR-T
ovarian cancer
Flag link:
AACR attendees told about tactics to tackle loss of T cell function in CAR T cell treatment
AACR attendees told about tactics to tackle loss of T cell function in CAR T cell treatment
Biopharma Reporter
Memorial Sloan Kettering
AACR
CAR-T
Flag link:
Precision reacquires rights to allogeneic CAR-Ts from Servier
Precision reacquires rights to allogeneic CAR-Ts from Servier
Fierce Biotech
Precision Biosciences
allogeneic cells
CAR-T
Servier
Flag link:
Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors
Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors
Fierce Biotech
Bluebird Bio
PsiOxus
CAR-T
solid tumors
Flag link:
5 takeaways from AACR, one of the year's top meetings on cancer drugs
5 takeaways from AACR, one of the year's top meetings on cancer drugs
BioPharma Dive
AACR
CAR-T
Merck
Roche
Sanofi
Synthorx
Eli Lilly
Bristol Myers Squibb
Flag link:
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy
MedCity News
Sanofi
M&A
Tidal Therapeutics
CAR-T
MRNA
Flag link:
Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting
Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting
Biopharma Reporter
Kite Pharma
Yescarta
CAR-T
Flag link:
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
BioPharma Dive
Bristol Myers Squibb
Bluebird Bio
ICER
Multiple Myeloma
CAR-T
Flag link:
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Fierce Pharma
Bristol Myers Squibb
Bluebird Bio
CAR-T
JNJ
Legend Biotech
Abecma
Flag link:
FDA approves first CAR-T cell therapy for multiple myeloma
FDA approves first CAR-T cell therapy for multiple myeloma
BioPharma Dive
Bristol-Myers Squibb
Bluebird Bio
CAR-T
Multiple Myeloma
Abecma
FDA
Flag link:
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Fierce Pharma
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Novartis
Kymriah
Flag link:
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Endpoints
Bristol-Myers Squibb
drug manufacturing
cell therapy
liso-cel
CAR-T
Flag link:
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
BioSpace
Bristol-Myers Squibb
CAR-T
Orva-Cel
Flag link:
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Fierce Pharma
FDA
Bristol-Myers Squibb
liso-cel
CAR-T
Flag link:
New study points to why CAR-T therapy may fail in some lymphoma patients
New study points to why CAR-T therapy may fail in some lymphoma patients
Fierce Biotech
CAR-T
lymphoma
Flag link:
Janssen flags accelerated approval milestone in Europe for CAR-T therapy
Janssen flags accelerated approval milestone in Europe for CAR-T therapy
Biopharma Reporter
JNJ
Janssen
CAR-T
EMA
Europe
cilta-cel
Flag link:
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
Fierce Pharma
Bristol-Myers Squibb
Celgene
liso-cel
M&A
CAR-T
Flag link:
Bold Predictions for Medtech in 2021
Bold Predictions for Medtech in 2021
Medical Devices and Diagnostics Industry
devices
Medtech
COVID-19
remote patient monitoring
telemedicine
home care
digital medicine
artificial intelligence
machine learning
robotic surgery
3D printing
Joe Biden
gene editing
microbiome
CAR-T
Flag link:
Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years
Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years
Endpoints
Factor Bioscience
cell therapy
MRNA
CAR-T
Flag link:
Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program
Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program
Endpoints
Autolus Therapeutics
ESMO
CAR-T
diffuse large B-cell lymphoma
layoffs
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »